First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

• Published in: British journal of clinical pharmacology Vol. 83; no. 5; pp. 991 - 1001
• Main Authors: Glatt, Sophie, Helmer, Eric, Haier, Birgit, Strimenopoulou, Foteini, Price, Graham, Vajjah, Pavan, Harari, Olivier A., Lambert, John, Shaw, Stevan
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.05.2017
• Subjects: Administration, Intravenous; Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacokinetics; anti‐IL17A; anti‐IL17F; bimekizumab; Clinical Trials; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Interleukin-17 - antagonists & inhibitors; interleukin‐17; Male; Middle Aged; psoriasis; Psoriasis - drug therapy; Severity of Illness Index; Treatment Outcome; UCB4940; Young Adult; anti-IL17A; interleukin-17; UCB4940; bimekizumab; anti-IL17F; psoriasis

Aims To assess safety, pharmacokinetics (PK) and clinical efficacy of bimekizumab (formerly UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL)‐17A and IL‐17F, in subjects with mild plaque psoriasis. Methods Randomized, double‐blind, first‐in‐human study of bimekiz...